Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/221578
Non-neutralizing anti-type I interferon autoantibodies could increase thrombotic risk in critical COVID-19 patients
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
During the COVID-19 pandemic, approximately 15% of patients with severe COVID-19 pneumonia were reported to have neutralizing anti-type I interferon (IFN) autoantibodies, which impaired the antiviral response and led to a poorer prognosis. However, the physiological impact of non-neutralizing autoantibodies remains unclear. In our cohort of COVID-19 patients admitted to intensive care, the presence of non-neutralizing anti-type I IFN autoantibodies increased the risk of thrombotic complications, likely via a cytokine carrier mechanism, prolonging the half-life of cytokines and dysregulating vascular endothelial function. Previous studies have associated non-neutralizing anti-type I IFN autoantibodies with an increased risk of cardiovascular complications in autoimmune diseases like systemic lupus erythematosus, but their relevance in infectious diseases remains uncertain. Stratifying anti-type I IFN autoantibodies based on their neutralizing capacity may have clinical significance not only in terms of susceptibility to infectious diseases but also in predicting cardiovascular and thrombotic events.
Matèries
Matèries (anglès)
Citació
Citació
FRAMIL, Mario, GARCÍA SERRANO, Lydia, MORANDEIRA-REGO, Francisco, LUCHORO, Juan francisco, ANTOLÍ GIL, Arnau, GÓMEZ VÁZQUEZ, José luis, SIERRA FORTUNY, Àngels, SOLANICH, Xavier. Non-neutralizing anti-type I interferon autoantibodies could increase thrombotic risk in critical COVID-19 patients. _Frontiers in Immunology_. 2025. Vol. 16. [consulta: 24 de gener de 2026]. ISSN: 1664-3224. [Disponible a: https://hdl.handle.net/2445/221578]